Business Context and Reporting Period
This Form 8-K Current Report was filed by X4 Pharmaceuticals, Inc. on April 24, 2025. The filing details the execution of a reverse stock split of the Company's common stock, which was approved by stockholders at a Special Meeting held on April 17, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions regarding capital structure.
Material Changes
- Reverse Stock Split: The Board of Directors approved a 1-for-30 reverse stock split of the Company's Common Stock.
- Effective Date: The split became effective at 12:01 a.m. Eastern Time on April 28, 2025.
- Share Reclassification: Every 30 shares of outstanding Common Stock were reclassified into one new share.
- Fractional Shares: No fractional shares were issued; holders entitled to fractional shares received cash in lieu thereof.
- Equity Adjustments: Proportional adjustments were made to shares under equity incentive plans, stock options, and outstanding warrants, including exercise and redemption prices.
- Trading Details: Trading on The Nasdaq Capital Market resumed on a split-adjusted basis on April 28, 2025, under the symbol "XFOR" with a new CUSIP number (98420X202).
Guidance, Outlook, and Risks
The filing includes a cautionary note regarding forward-looking statements, noting that expectations about the effects of the reverse stock split are not guarantees of performance. Identified risks include:
- Unfavorable outcomes of planned clinical trials and studies.
- Technical, scientific, or commercial delays in product candidate programs.
- Uncertainty regarding regulatory approval for clinical trials or product marketing.
- Intellectual property protection uncertainties.
- Challenges in advancing and commercializing mavorixafor for chronic neutropenia or optimizing the promotion of XOLREMDI.
Investor Verification Checklist
- Verify the new CUSIP number (98420X202) for the Common Stock.
- Confirm the 1-for-30 split ratio and the effective date of April 28, 2025.
- Review the treatment of fractional shares (cash in lieu) for personal holdings.
- Check adjusted exercise prices and share counts for any held stock options or warrants.
- Monitor trading activity on The Nasdaq Capital Market under the symbol "XFOR" post-split.